| News
New at Switzerland Innovation Park Basel Area: Coretag
09.01.2020
Coretag, a new dynamic biotech company, launches a radioligand platform technology for a range of therapeutic and diagnostic purposes. A radioligand is a radioactive biochemical that is used for diagnostic and therapeutic procedures or for studying the body’s receptor systems. Injected into the relevant tissue or administered into the bloodstream, the radioligand binds to its receptor on tumor cells surfaces. Coretag is determined to rapidly improve care with this platform technology.
Coretag: Elmer Monster, Ermond van Beek, Markwin Maring and Jan van Bodegom (from left to right), img: Roderik van Nispen
Coretag aims to launch an application named NC-Scan for use in patients in 2021. Based on selectively binding to necrotic cells, the NC-Scan will be the world’s first clinical application to determine chemotherapy efficacy within the first week of therapy. Clinical trials with patients with specific solid tumors will start early 2020 at world-renowned leading cancer institutes in Europe and the USA.
This application is a basis for the development of therapeutic agents. Two radioligands therapeutics are in the pipeline, both for the treatment of solid tumor cancer-types. Based on brachy-therapy and hyperthermia, they will have major impact as adjuvant to many existing forms of cancer therapies that are not 100% effective yet.
Coretag’s executive team, originally from the Netherlands, sets its base at the Switzerland Innovations Park Basel Area. They work focused on developing their business. “We are very happy with this location. The atmosphere is dynamic and based on progress. That is how we stand. Great to be here”, says CFO Elmer Monster.
Links
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
docdok.health involved in coronavirus research project
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.
Read More
Celonic agrees cooperation to combat coronavirus
The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.
Read More
Idorsia receives payment of 45 million US dollars
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..
Read More
Humard robot disinfects using UV light
Humard has developed a robot that can disinfect spaces using UV light. For this, the system manufacturer from the canton of Jura has adapted a mobile industrial robot that is otherwise used in warehouse logistics.
Read More
Roche authorized to distribute coronavirus antibody tests
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.
Read More
Basel is the most popular Swiss location for headquarters
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.
Read More
